#High Tide #medical cannabis #Remexian

High Tide Inc. Expands Its Footprint in Medical Cannabis

High Tide Inc. has recently announced its entry into the rapidly growing German medical cannabis market through a significant acquisition. The company, which is publicly traded on Nasdaq and TSXV, is acquiring a 51% stake in Remexian Pharma GmbH for an estimated initial purchase price of €27.2 million. This move is expected to significantly bolster High Tide's presence in Europe’s lucrative cannabis market, especially following the recent legislative changes that have led to an unprecedented demand for medical cannabis in Germany.

A Strategic Partnership

Founded in 2018 and located near Berlin, Remexian is recognized as a leading pharmaceutical company specialized in the importation and wholesale distribution of medical cannabis. The firm operates under stringent EU regulations and has built an impressive infrastructure that allows it to source cannabis products from multiple countries. The acquisition marks High Tide's strategic commitment to providing high-quality, affordable medical cannabis across Europe.

Raj Grover, the founder and CEO of High Tide, expressed his enthusiasm for the acquisition, highlighting how Remexian's operational ethos aligns closely with High Tide’s dedication to low-cost pricing structures. He noted, "Our combined strengths and procurement expertise will create a robust platform for growth in Europe." As part of this acquisition, High Tide also gains the option to buy the remaining stake in Remexian within five years.

Remexian's Market Impact

Over the last year, demand for medical cannabis in Germany has skyrocketed, with the number of patients rising sharply from approximately 250,000 to nearly 900,000. This surge has significantly increased import volumes, with a record total of 43.3 metric tonnes of cannabis imported in the second quarter of 2025. Remexian played a crucial role in this market, selling 7 tonnes of cannabis flower in that same quarter, contributing to 16% of all imports into Germany.

The financial outlook appears promising for the partnership, with Remexian projected to add around CAD 100 million in top-line revenue for High Tide. The strategic alignment serves both companies aiming to expand their foothold in a market projected to reach nearly €1 billion in revenue.

Looking Ahead

Germany’s Consumer Cannabis Act, passed in April 2024, is driving notable changes in the cannabis landscape, which could present both challenges and opportunities. Despite potential restrictions related to telemedicine and delivery services that may arise through legislative reviews, High Tide remains optimistic about continued market growth.

Markus Wenner, Co-Founder of Remexian, emphasized the synergistic benefits of this partnership, stating, “Combining our distribution network with High Tide's Canadian supply access sets a stage for exceptional growth.